Home >> Signaling Pathways >> Apoptosis

Apoptosis(凋亡)

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

Products for  Apoptosis

  1. Cat.No. 产品名称 Information
  2. GC65253 PCC0208017 PCC0208017 是有效的微管亲和力调节激酶 MARK3/MARK4 抑制剂,IC50 值分别为 1.8 和 2.01 nM。 PCC0208017 对 MARK1 和 MARK2 的抑制活性要低得多,IC50 值分别为 31.4 和 33.7 nM。 PCC0208017 在体内外都抑制神经胶质瘤进展。PCC0208017 破坏微管动力学并诱导 G2/M 期细胞周期停滞和细胞凋亡。PCC0208017 具有强大的抗肿瘤活性并显示出良好的 BBB 通透性。
  3. GC65249 STL127705 STL127705 (Compound L) 是一种有效的 Ku 70/80 异二聚体蛋白 Ku 70/80 heterodimer protein 抑制剂,IC50 为 3.5 μM。STL127705 通过抑制 DNA-PKCS 激酶的激活干扰 Ku70/80 与 DNA 的结合。STL127705 显示出抗增殖和抗肿瘤活性。 STL127705 诱导细胞凋亡 (apoptosis) 。
  4. GC65200 Nevanimibe hydrochloride

    PD-132301 hydrochloride; ATR101 hydrochloride

    Nevanimibe hydrochloride (PD-132301 hydrochloride) 是一种口服有效的,选择性酰基辅酶 A:胆固醇 O-酰基转移酶 1 (ACAT1) 抑制剂,EC50 为 9 nM。Nevanimibe hydrochloride 抑制 ACAT2,EC50 为 368 nM。Nevanimibe hydrochloride 诱导细胞凋亡 (apoptosis),并具有抗肾上腺皮质癌的潜力。
  5. GC65168 Imifoplatin

    PT-112

    Imifoplatin (PT-112) 是一种铂类药物,属于磷铂家族。Imifoplatin 具有抗肿瘤活性。
  6. GC65163 Ardisiacrispin B

    百两金皂苷B

    Ardisiacrispin B在多因素耐药癌细胞中显示细胞毒性作用,通过铁中毒和凋亡细胞死亡。
  7. GC65143 MKC-1

    Ro-31-7453

    MKC-1 (Ro-31-7453) 是一种口服有效的细胞周期抑制剂,具有广泛的抗肿瘤活性。MKC-1 抑制 Akt/mTOR 通路。通过结合一系列不同的细胞蛋白,包括微管蛋白 (tubulin) 和导入蛋白 β (importin β) 家族成员,MKC-1 阻止细胞有丝分裂并诱导细胞凋亡 (apoptosis)。
  8. GC65107 Ac-FEID-CMK TFA Ac-FEID-CMK TFA 是一种有效的斑马鱼特异性 GSDMEb 衍生肽抑制剂。Ac-FEID-CMK TFA 可减轻感染性休克的死亡率和肾损伤。Ac-FEID-CMK TFA 在体内可抑制焦亡,减轻败血性 AKI (急性肾损伤)。Ac-FEID-CMK TFA 可抑制 caspy2 介导的非典型炎症小体通路。
  9. GC65095 L-Glutamic acid-d5

    L-谷氨酸 d5

    L-Glutamic acid-d5 是 L-Glutamic acid 的氘代物。L-Glutamic acid 作为一种兴奋性氨基酸神经递质,为谷氨酸盐受体所有亚型(代谢型红藻氨酸、NMDA 和 AMPA)的激动剂。对 DA 从多巴胺能神经末梢释放的过程有激动作用。
  10. GC65081 CALP1 TFA CALP1 TFA 是一种钙调蛋白 (CaM) 激动剂 (Kd 为 88 µM),与 CaM EF-hand/Ca2+ 结合位点结合。CALP1 TFA 通过抑制钙通道 (calcium channel) 的开放来阻止钙的流入和凋亡 (IC50 为 44.78 µM)。CALP1 TFA 阻止谷氨酸受体 ( glutamate receptor channels) 通道,并阻止存储操作的非选择性阳离子通道。CALP1 TFA 激活 CaM 依赖性磷酸二酯酶 (phosphodiesterase) 活性。
  11. GC65071 PD-1/PD-L1-IN 3 TFA PD-1/PD-L1-IN 3 TFA,一种大环肽,是一种有效和选择性的 PD-1/PD-L1 和 CD80/PD-L1 的相互作用抑制剂。PD-1/PD-L1-IN 3 TFA 通过与 PD-L1 结合来干扰 PD-L1 与 PD-1 和 CD80 的结合,IC50 值分别为 5.60 nM 和 7.04 nM。PD-1/PD-L1-IN 3 TFA 可用于各种疾病的研究,包括癌症和传染病。详细信息请参考专利文献 WO2014151634A1 中的化合物 No.1。
  12. GC65066 Prodigiosin hydrochloride

    PRODIGIOSIN盐酸盐,Prodigiosine hydrochloride

    A natural red pigment and antibiotic
  13. GC65043 Haemanthamine Haemanthamine 是从 Amaryllidaceae 植物中分离出来的一种蛇毒碱样生物碱,具有强大的抗癌活性。Haemanthamine 靶向核糖体以在翻译的延长阶段抑制蛋白质的生物合成。Haemanthamine 具有促凋亡,抗氧化剂,抗病毒,抗疟疾和抗惊厥活性。
  14. GC65033 Tislelizumab

    替雷利珠单抗

    Tislelizumab 是一种对 PD-1 受体具有高结合亲和力的单克隆抗体,可最大限度地减少 Fcγ 受体与巨噬细胞的结合,从而消除抗体依赖性吞噬作用,这是一种 T 细胞清除机制,可对抗 PD-1 治疗的潜在耐药性。Tislelizumab 可用于晚期鳞状非小细胞肺癌的研究。

  15. GC65031 Belimumab

    贝利木单抗,LymphoStat B

    Belimumab (LymphoStat B) 是一种人 IgG1Λ 单克隆抗体,可抑制 B 细胞激活因子 (BAFF)。Belimumab 可用于系统性红斑狼疮 (SLE) 研究。
  16. GC65010 Bortezomib-d8

    PS-341-d8; LDP-341-d8; NSC 681239-d8

    Bortezomib-d8 (PS-341-d8) 是 Bortezomib 的氘代物。Bortezomib (PS-341) 是一种可逆性和选择性的蛋白酶体 (proteasome) 抑制剂,通过靶向苏氨酸残基有效抑制 20S 蛋白酶体 (Ki=0.6 nM)。Bortezomib 破坏细胞周期、诱导细胞凋亡以及抑制核因子 NF-κB。Bortezomib 是第一种蛋白酶体抑制剂,具有抗癌活性。
  17. GC65004 Apostatin-1

    Apt-1

    Apostatin-1 (Apt-1) is a novel TRADD inhibitor. Apostatin-1 binds to a pocket on the N-terminal TRAF2-binding domain of TRADD (TRADD-N). Apostatin-1 inhibits bortezomib-induced apoptosis and RIPK1-dependent apoptosis (RDA) with an IC50 of about 1 μM.
  18. GC64995 RIPGBM A prodrug of cRIPGBM
  19. GC64993 Chicoric acid

    菊苣酸; Cichoric acid; Dicaffeoyltartaric acid

    A dicaffeoyl ester with diverse biological activities
  20. GC64992 YH-306 YH-306 是一种抗肿瘤剂。YH-306 通过 FAK 通路抑制结直肠肿瘤的生长和转移。 YH-306 显着抑制结直肠癌细胞的迁移和侵袭。YH-306 有效抑制不受抑制的增殖并诱导细胞凋亡 (apoptosis)。YH-306 抑制 FAK、c-Src、桩蛋白和 PI3K、Rac1 的激活以及 MMP2 和 MMP9 的表达。YH-306 还抑制肌动蛋白相关蛋白 (Arp2/3) 复合物介导的肌动蛋白聚合。
  21. GC64980 MV1 MV1 是凋亡抑制因子 IAP 的拮抗剂,与 HaloTag 配体结合,导致 HaloTag 融合蛋白的蛋白敲除。
  22. GC64971 DDO-7263 DDO-7263 是一种 1,2,4-Oxadiazole 衍生物,是一种有效的 Nrf2-ARE 激活剂。DDO-7263 通过与 Rpn6 结合上调 Nrf2,从而阻断 26S 蛋白酶体的组装和随后泛素化 Nrf2 的降解。DDO-7263 诱导 Nrf2 易位进入细胞核。DDO-7263 抑制 NLRP3 炎性体激活。DDO-7263 具有抗炎活性,并且有潜力用于神经退行性疾病(例如帕金森病 (PD)) 的研究。
  23. GC64951 GSK963

    (S)-2,2-二甲基-1-(5-苯基-4,5-二氢-1H-吡唑-1-基)丙-1-酮

    GSK'963 is a chiral small-molecule inhibitor of RIP1 kinase (RIPK1) with an IC50 of 29 nM in FP binding assays. It is >10?000-fold selective for RIP1 over 339 other kinases.
  24. GC64946 SRT 2183 SRT2183 is a small-molecule activator of the sirtuin subtype SIRT1, currently being developed by Sirtris Pharmaceuticals.
  25. GC64938 AZD-7648 An inhibitor of DNA-PK
  26. GC64936 TD52 dihydrochloride A derivative of erlotinib
  27. GC20020 3,4-Dihydroxyflavone

    3',4'-二羟基黄酮

    A synthetic flavonoid with diverse biological activities
  28. GC64864 EJMC-1 EJMC-1 是一种中度有效的 TNF-α 抑制剂,IC50 为 42 μM。
  29. GC64862 Tricetin

    三粒小麦黄酮

    Tricetin 是一种有效的竞争性 Keap1-Nrf2 蛋白相互作用 (PPI) 抑制剂。Tricetin 作用于帕金森病模型,通过激活 Nrf2/HO-1 信号通路和阻止线粒体依赖性细胞凋亡 (apoptosis) 通路来保护 6-OHDA 诱导的神经毒性。
  30. GC64855 PD-1/PD-L1-IN-23 PD-1/PD-L1-IN-23 是一种有效的、具有口服活性的 PD-1/PD-L1 抑制剂。PD-1/PD-L1-IN-23 是 L7 的酯类前药。L7 是一种苯并[c][1,2,5]恶二唑衍生物,在生物学上被评估为 PD-L1 的抑制剂。PD-1/PD-L1-IN-23 在同基因和 PD-L1 人源化小鼠的肿瘤模型中显示出显着的抗肿瘤作用。
  31. GC64839 Varlilumab

    伐立鲁单抗,CDX-1127

    Varlilumab (CDX-1127) 是一种首创的人 IgG1 抗 CD27 单克隆抗体。Varlilumab 具有抗肿瘤活性。
  32. GC64786 Hellebrigenin

    蟾蜍它里定

    Hellebrigenin,属于心脏活性类固醇的丁二烯内酯之一,从中药中分离出来。Hellebrigenin 诱导 DNA 损伤和细胞周期 G2/M 阻滞。 Hellebrigenin 触发线粒体介导的细胞凋亡。
  33. GC64768 PK9327 PK9327 是一种小分子稳定剂,靶向空腔的 p53 癌症突变。
  34. GC64767 ISIS 104838 ISIS 104838是一种反义寡核苷酸药物,可减少肿瘤坏死因子 (TNF-alpha) 的产生。TNF-alpha 可以导致类风湿关节炎关节疼痛和肿胀。
  35. GC64762 3,6-Dihydroxyflavone

    3,6-二羟基黄酮,3,6-DHF

    3,6-Dihydroxyflavone 是一种抗癌剂。3,6-Dihydroxyflavone 剂量和时间依赖性地降低细胞活力并通过激活半胱天冬酶级联、切割聚 (ADP-核糖) 聚合酶 (PARP) 诱导 apoptosis。3,6-Dihydroxyflavone 增加细胞内氧化应激和脂质过氧化。
  36. GC64726 10-Formyl-5,8-dideazafolic acid 10-Formyl-5,8-dideazafolic acid 是一种胸苷酸合成酶 (thymidylate synthase) 抑制剂。
  37. GC64674 ABBV-167 ABBV-167 是一种 BCL-2 抑制剂 venetoclax 的磷酸盐前药。
  38. GC64662 Helichrysetin

    蜡菊亭; 4,2',4'-三羟基-6'-甲氧基查耳酮

    Helichrysetin,分离于 Helichrysum odoratissimum 的花朵中, 是一种ID2 (DNA 结合抑制剂 2) 抑制剂,可抑制DCIS (原位导管癌) 的形成。Helichrysetin 对细胞生长具有很强的抑制作用,并且能够诱导 A549 细胞凋亡 (apoptosis)。
  39. GC64649 Cjoc42 Cjoc42 是一种能够与gankyrin 结合的化合物。Cjoc42 以剂量依赖性方式抑制 gankyrin 活性。Cjoc42 可防止通常与大量 gankyrin 相关的 p53 蛋白水平降低。Cjoc42 恢复 p53 依赖性转录和对 DNA 损伤的敏感性。
  40. GC64645 Sappanchalcone Sappanchalcone 从 Caesalpinia sappan L. 中提取的黄酮类化合物,诱导人结肠癌细胞凋亡 (apoptosis)。
  41. GC64619 β-Ionone

    β-紫罗兰酮

    β-Ionone 可有效诱导胃腺癌细胞 SGC7901 凋亡 (apoptosis)。具有抗肿瘤活性。
  42. GC64561 Toripalimab

    特瑞普利单抗

    Toripalimab 是首个国产抗肿瘤 PD-1 抗体。Toripalimab 是一种靶向 PD-1 的选择性人源化单克隆抗体。Toripalimab 能够与 PD-1 结合并阻断与其配体相互作用。Toripalimab 具有强效抗肿瘤作用,可用于黑色素瘤、肺癌、消化道肿瘤、肝胆和胰腺肿瘤、神经内分泌肿瘤、鼻咽癌和尿路上皮癌等肿瘤的研究。

  43. GC64485 HXR9 hydrochloride HXR9 hydrochloride 是一种细胞渗透性肽,是 HOX/PBX 相互作用 (HOX/PBX interaction) 的竞争性拮抗剂。HXR9 hydrochloride 拮抗 HOX 与第二转录因子 (PBX) 之间的相互作用,PBX 与旁系同源基因组 1 至 8 中的 HOX 蛋白结合。HXR9 hydrochloride 选择性地减少细胞增殖并促进 HOXA/PBX3 基因高水平表达的细胞,例如 MLL 重排的白血病细胞中的细胞凋亡 (apoptosis)。
  44. GC64467 Lisaftoclax

    APG-2575; Bcl-2/Bcl-xl inhibitor 1

    APG-2575 (lisaftoclax) is a dual Bcl-2 and Bcl-xl inhibitor with IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively.
  45. GC52115 S-99 An inhibitor of ASK1
  46. GC52104 Ponatinib (hydrochloride)

    泊那替尼盐酸盐,AP24534 hydrochloride

    An inhibitor of native and mutant Bcr-Abl
  47. GC52101 Brazilein A phytochemical with diverse biological activities
  48. GC52076 Temozolomide Acid

    3,4-二氢-3-甲基-4-氧代咪唑并[5,1-D]-1,2,3,5-四嗪-8-甲酰胺酸

    An active metabolite of temozolomide
  49. GC52057 QN523 An anticancer agent
  50. GC52049 Myricetin 3-galactoside

    杨梅素 3-O-半乳糖苷

    A flavonoid with diverse biological activities
  51. GC19959 Methylprednisolone acetate

    泼尼松龙EP杂质

    A synthetic glucocorticoid and an ester form of methylprednisolone

Items 501 to 550 of 2733 total

per page
  1. 9
  2. 10
  3. 11
  4. 12
  5. 13

Set Descending Direction